Apellis Pharmaceuticals Inc (APLS) Stock Price, Quote & News

Company Profile

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproli...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 977 5700

Website: apellis.com

Address:

100 Fifth Avenue, Waltham, United States

Georgeson Mar. 12 at 6:36 PM

$APLS Where is the freaking bottom? Cedric and other insiders if they know anything about running a public company should buy some shares on the open market. So glad I sold all my shares at $26 plus and bought sndx. But I am tempted to buy back in.

0 · Reply

Spanner1968 Mar. 11 at 7:14 PM

$APLS POS, trying to shake everyone out.....

1 · Reply

scott52 Mar. 11 at 4:33 PM

$APLS Bought back at $19.15. For a trade. Saved 15% dumping at $22.50. I can't make any money holding this stock (in fact, I lost money). Figured I may as well try trading it to claw something back. Man, I don't trust this stock AT ALL. I won't be suprised if it plummets to $16 now that I own it again.

0 · Reply

RunnerSignals Mar. 10 at 8:38 PM

Top stock upgrades today in the BUZZ $APLS $ASML $CAVA $IQV $PLUG steady gains post-rating changes, correlation to sector news, late buyers pushed close higher https://stocksrunner.com/news/2026-03-10-top-stock-upgrades-today-in-the-buzz

0 · Reply

Longboardsoul Mar. 10 at 6:27 PM

$APLS I think we can all agree that the real winner here is Cedric's ex wife. Homegirl realized he was a loser and split. Hope she took him for a few mil. Guy is a baby back Belgian bitch

0 · Reply

Whiskeyunderthebed Mar. 10 at 3:00 PM

$APLS

0 · Reply

The_Fudge_ster Mar. 10 at 2:15 PM

$APLS amazing watching $DNTH rip while APLS just sits and wallows in the misery of the teens. Amazing how a company that claims to be the leader in complement has whiffed so badly while others succeed.

1 · Reply

philosophernutz Mar. 8 at 1:34 AM

$APLS Get ready boys. Dolstens was hired to help sell APLS. His stock options fully accelerate if there's a change in control of the company. Form 3 Mar 3, 2026 Initial Statement of Beneficial Ownership. Confirms Dolsten currently owns 0 shares outright. He is purely an "Equity-Incentivized" director. Form 4 Mar 3, 2026 Grant of 24,135 Options and 14,312 RSUs. The exercise price for his options is $20.96. This is his "breakeven" point. The Trigger Full Acceleration SEC Exhibit 10.1 The contract explicitly states all 38,447 units vest immediately upon a "Change in Control.

3 · Reply

Whiskeyunderthebed Mar. 7 at 4:45 PM

$APLS This is what we need: Servier to build cancer drug pipeline with $2.5B purchase of Day One

0 · Reply

erevnon Mar. 5 at 2:58 PM

Mizuho maintains Apellis Pharmaceuticals $APLS at Neutral and raises the price target from $19 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

Apellis Pharmaceuticals, Inc. (APLS) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Mar 2, 2026, 7:00 AM EST - 13 days ago

Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors

Feb 24, 2026, 11:48 AM EST - 18 days ago

Apellis Pharmaceuticals, Inc. (APLS) Q4 2025 Earnings Call Transcript

Feb 24, 2026, 7:05 AM EST - 19 days ago

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 23, 2026, 7:00 AM EST - 20 days ago

Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference

Feb 19, 2026, 7:00 AM EST - 24 days ago

Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting

Feb 10, 2026, 7:00 AM EST - 4 weeks ago

Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial Results

Jan 27, 2026, 6:02 PM EST - 6 weeks ago

TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600

AEIS AHR AMRX BROS CADE CIVI CMA

Jan 21, 2026, 1:14 PM EST - 7 weeks ago

Apellis Valuation Ignores Empaveli Potential, Says Analyst

Jan 12, 2026, 6:16 PM EST - 2 months ago

Apellis Pharmaceuticals, Inc. (APLS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 7:00 AM EST - 2 months ago

Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 7:00 AM EST - 2 months ago

Apellis Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 3, 2025, 5:05 PM EST - 3 months ago

The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

Dec 3, 2025, 4:43 PM EST - 3 months ago

Apellis Pharmaceuticals, Inc. (APLS) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 2, 2025, 6:53 PM EST - 3 months ago

Apellis Pharmaceuticals, Inc. (APLS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Nov 25, 2025, 7:00 AM EST - 3 months ago

Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

Nov 12, 2025, 4:41 PM EST - 4 months ago

Apellis Pharmaceuticals, Inc. (APLS) Presents at Stifel 2025 Healthcare Conference Transcript

Nov 12, 2025, 7:00 AM EST - 4 months ago

Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years

Nov 5, 2025, 7:00 AM EST - 4 months ago

Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference

Oct 30, 2025, 8:16 PM EDT - 4 months ago

Apellis Pharmaceuticals, Inc. (APLS) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 7:05 AM EDT - 4 months ago

Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results

Oct 20, 2025, 7:00 AM EDT - 5 months ago

New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week

Oct 16, 2025, 7:00 AM EDT - 5 months ago

Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results

Sep 30, 2025, 4:34 PM EDT - 5 months ago

Apellis Pharmaceuticals: Maintaining "Buy" Rating With Continued EMPAVELI Expansions Beyond PNH And C3G-Disorders

Sep 9, 2025, 12:55 PM EDT - 6 months ago

Apellis Pharmaceuticals, Inc. (APLS) Presents At Baird Global Healthcare Conference (Transcript)

Sep 4, 2025, 11:20 AM EDT - 6 months ago

Apellis Pharmaceuticals, Inc. (APLS) Presents At Cantor Global Healthcare Conference 2025 (Transcript)

Sep 3, 2025, 11:24 AM EDT - 6 months ago

Apellis Pharmaceuticals, Inc. (APLS) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Aug 14, 2025, 12:12 PM EDT - 7 months ago

Apellis Pharmaceuticals: Restart Of Growth Story After Empaveli's New Approval

Aug 2, 2025, 4:23 AM EDT - 8 months ago

Apellis Pharmaceuticals, Inc. (APLS) Q2 2025 Earnings Call Transcript

Aug 1, 2025, 2:29 PM EDT - 8 months ago

Apellis Pharmaceuticals: The Picture Becomes Clearer

Jul 31, 2025, 7:05 AM EDT - 8 months ago

Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results

Jul 29, 2025, 12:12 PM EDT - 8 months ago

FDA Approval For Empaveli Marks Key Milestone In Apellis' Rare Disease Portfolio

Jul 28, 2025, 7:19 PM EDT - 8 months ago

FDA Approves Apellis' EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older

Jul 24, 2025, 7:00 AM EDT - 8 months ago

Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results

Jul 15, 2025, 7:00 AM EDT - 8 months ago

Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting

Jul 1, 2025, 7:35 AM EDT - 9 months ago

Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli® (systemic pegcetacoplan)

Jul 1, 2025, 7:00 AM EDT - 9 months ago

Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)

Jun 6, 2025, 9:15 AM EDT - 10 months ago

Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN

Jun 4, 2025, 7:00 AM EDT - 10 months ago

Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

May 20, 2025, 9:28 AM EDT - 10 months ago

Apellis Pharmaceuticals: Have Some Patience

May 7, 2025, 1:18 PM EDT - 11 months ago

Apellis Pharmaceuticals, Inc. (APLS) Q1 2025 Earnings Call Transcript

May 7, 2025, 7:00 AM EDT - 11 months ago

Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results

May 6, 2025, 7:00 AM EDT - 11 months ago

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

Apr 30, 2025, 7:00 AM EDT - 11 months ago

Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results

Apr 21, 2025, 7:00 AM EDT - 11 months ago

Apellis Announces Craig Wheeler to Join the Board of Directors

Apr 1, 2025, 2:11 PM EDT - 1 year ago

FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals

Apr 1, 2025, 7:00 AM EDT - 1 year ago

Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

Mar 5, 2025, 2:06 PM EST - 1 year ago

Apellis Pharmaceuticals: A Mixed Bag

Mar 5, 2025, 2:04 PM EST - 1 year ago

Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst

Mar 2, 2025, 2:08 AM EST - 1 year ago

Apellis Pharmaceuticals, Inc. (APLS) Q4 2024 Earnings Call Transcript

Georgeson Mar. 12 at 6:36 PM

0 · Reply

Spanner1968 Mar. 11 at 7:14 PM

$APLS POS, trying to shake everyone out.....

1 · Reply

scott52 Mar. 11 at 4:33 PM

0 · Reply

RunnerSignals Mar. 10 at 8:38 PM

0 · Reply

Longboardsoul Mar. 10 at 6:27 PM

$APLS I think we can all agree that the real winner here is Cedric's ex wife. Homegirl realized he was a loser and split. Hope she took him for a few mil. Guy is a baby back Belgian bitch

0 · Reply

Whiskeyunderthebed Mar. 10 at 3:00 PM

$APLS

0 · Reply

The_Fudge_ster Mar. 10 at 2:15 PM

1 · Reply

philosophernutz Mar. 8 at 1:34 AM

3 · Reply

Whiskeyunderthebed Mar. 7 at 4:45 PM

$APLS This is what we need: Servier to build cancer drug pipeline with $2.5B purchase of Day One

0 · Reply

erevnon Mar. 5 at 2:58 PM

Mizuho maintains Apellis Pharmaceuticals $APLS at Neutral and raises the price target from $19 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

Spanner1968 Mar. 4 at 6:04 PM

$APLS well Mikael Dolstens made an impact then!

2 · Reply

buylowandwait Mar. 4 at 4:13 PM

$APLS Though the asset of this company should be valued far more than the current enterprise value. The management team leaves bad taste for its management style, and they are going to milk as much from shareholders as they can.

1 · Reply

Johnquest123 Mar. 3 at 2:56 PM

$APLS let the good times roll and keep on rolling!

0 · Reply

scott52 Mar. 3 at 1:45 PM

$APLS $16-$19. It's inevitable. Biotechs don't go up on no guidance no good news. They only go down.

1 · Reply

Jennifur Feb. 27 at 12:43 PM

$APLS Not much has changed here I'm afraid.....still just an ATM for insiders...little more.

1 · Reply

ZacksResearch Feb. 25 at 2:01 PM

$APLS dips 20.8% in six months — is there a turnaround on the horizon? Q4 loss of 47 cents per share, wider than expected Revenues beat estimates at $199.9M, despite a 6% YoY decline Empaveli sales up 50%, driven by strong early launch in C3G and IC-MPGN Full analysis here 👉 https://www.zacks.com/stock/news/2874888/apellis-q4-loss-wider-than-expected-revenues-decline-yy?cid=sm-stocktwits-2-2874888-body-35025&ADID=SYND_STOCKTWITS_TWEET_2_2874888_BODY_35025

0 · Reply

ZacksResearch Feb. 25 at 1:01 PM

$APLS just sent mixed signals — wider loss, but some serious product momentum Q4 loss came in wider than expected and Syfovre sales slipped 8%, yet revenues topped estimates and Empaveli surged 50% on a strong new indication launch. That’s a clear divergence inside the portfolio. Is Empaveli the growth engine that offsets the pressure? Get the full breakdown 👉 https://www.zacks.com/stock/news/2874888/apellis-q4-loss-wider-than-expected-revenues-decline-yy?cid=sm-stocktwits-2-2874888-teaser-35015&ADID=SYND_STOCKTWITS_TWEET_2_2874888_TEASER_35015

0 · Reply

Georgeson Feb. 24 at 4:35 PM

$APLS I have not followed too closely but the wording "Apellis Pharmaceuticals Inc. anticipates its cash and cash equivalents, combined with projected sales from EMPAVELI and SYFOVRE, will fund operating expenses and capital expenditures for at least the next 12 months" has changed? Before wasn't it enough to fund until profitability?

1 · Reply

Spanner1968 Feb. 24 at 2:48 PM

$APLS big pharma must be eying this up now!

1 · Reply

Whiskeyunderthebed Feb. 24 at 2:13 PM

$APLS there is NO growth. SYFOVRE U.S. net product revenue for the three and twelve months ended December 31, 2025, was $155.2 million and $586.9 million, respectively, compared to $167.8 million and $611.8 million for the same periods in 2024. EMPAVELI U.S. net product revenue for the three and twelve months ended December 31, 2025, was $35.1 million and $102.4 million, respectively, compared to $23.4 million and $98.1 million for the same periods in 2024.

2 · Reply

Whiskeyunderthebed Feb. 24 at 2:07 PM

$APLS weather again....

1 · Reply

Whiskeyunderthebed Feb. 24 at 2:01 PM

$APLS of course no guidance...

0 · Reply

Market Cap	2.42B
Revenue (ttm)	1.00B
Net Income (ttm)	22.39M
EPS (ttm)	N/A
PE Ratio	145.69
Forward PE	N/A
Profit Margin	2.23%
Debt to Equity Ratio	1.23

Volume	1,716,800
Avg Vol	2,840,116
Day's Range	N/A - N/A
Shares Out	127.83M
Stochastic %K	25%
Beta	0.26
Analysts	Strong Sell
Price Target	$33.74